Filing Flows › Haemonetics (HAE) › R&D spending
Haemonetics (HAE) R&D spending by quarter
Haemonetics' R&D spending was $17.0M in Q2 FY27 (second quarter fiscal 2027), +5% from Q1 FY27. Over the last 6 quarters it ranged from $14.2M (Q3 FY26) to $17.0M (Q2 FY27).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q2 FY27 | $17.0M | +5% | +15% |
| Q1 FY27 | $16.2M | +12% | -0.4% |
| Q4 FY26 | $14.4M | +2% | — |
| Q3 FY26 | $14.2M | -5% | — |
| Q2 FY26 | $14.9M | -9% | — |
| Q1 FY26 | $16.3M | — | — |
Q2 FY27 at a glance
Haemonetics, Q2 FY27: revenue $358M (+9% year over year), operating margin 21.0%, net earnings $46.3M, operating cash flow $128M. The chart follows the revenue to costs, profit and cash.
Questions
What is Haemonetics' R&D spending?
Haemonetics' R&D spending was $17.0M in Q2 FY27 (second quarter fiscal 2027), +5% from Q1 FY27.
How has Haemonetics' R&D spending changed?
Over the last 6 quarters it ranged from $14.2M (Q3 FY26) to $17.0M (Q2 FY27).